Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

CVS Health is partnering with Novo Nordisk to help distribute its Wegovy GLP-1 weight-loss drug at lower prices. The new threat has Eli Lilly investors running scared, but Wall Street analysts ...